Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Lida Bubuteishvili Pacaud"'
Autor:
Jordan M. Schecter, Carolyn C. Jackson, Arnob Banerjee, Saad Z. Usmani, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Joris Diels, Imtiaz A. Samjoo, Anja Haltner, Martin Vogel, William Deraedt, Suzy Van Sanden, Hong Tian, Chris Cameron, Satish Valluri, Thomas Martin, Ashraf Garrett
Publikováno v:
Current Medical Research and Opinion. 37:1779-1788
OBJECTIVE This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300-460 × 106 CAR-positive T-cells for the treatment of patients with relapsed or ref
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38bda08b1772522d0b6d841153f99e1c
https://doi.org/10.1080/03007995.2021.1953456
https://doi.org/10.1080/03007995.2021.1953456
Autor:
Miguel-Angel Perales, Raghav Chawla, Paul L. Martin, Manali Kamdar, Cameron J. Turtle, Joshua P. Sasine, Eric Bleickardt, Kevin J. Curran, Marcelo C. Pasquini, Sarah Nikiforow, Peiman Hematti, Lan Yi, Theodore W. Laetsch, Amy K. Keating, Monalisa Ghosh, Steven P. Margossian, Michael A. Pulsipher, Joseph Rosenthal, Amy Moskop, Dana Salzberg, Matthew J. Frigault, Patricia Steinert, Christine L Phillips, Rayne H. Rouce, Stephan A. Grupp, Daniel J. Landsburg, Mary M. Horowitz, Zhen-Huan Hu, Lida Bubuteishvili Pacaud, Samantha Jaglowski, Frederick L. Locke
Publikováno v:
Blood Advances. 4:5414-5424
Tisagenlecleucel is a CD19 chimeric antigen receptor (CAR) T-cell therapy approved for treatment of pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and adults with non-Hodgkin lymphoma (NHL). The initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12f0b2c19d3458a4c797ee6146969958
https://doi.org/10.1182/bloodadvances.2020003092
https://doi.org/10.1182/bloodadvances.2020003092
Autor:
Irina Gershgorin, Rakesh Awasthi, Koen van Besien, Lida Bubuteishvili Pacaud, Abhijit Chakraborty, Gilles Salles, Nina D. Wagner-Johnston, Marie José Kersten, Constantine S. Tam, Peter Borchmann, Edmund K. Waller, Özlem Anak, Jufen Chu, Christopher del Corral, Iulian Pruteanu-Malinici, Stephen J. Schuster, Richard T. Maziarz, Samantha Jaglowski, Ulrich Jäger, Edward Waldron, Karen Thudium Mueller, Stephen Ronan Foley
Publikováno v:
Blood advances, 4(3), 560-572. American Society of Hematology
The anti-CD19 chimeric antigen receptor (CAR)–T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5fd2f26636dd2184ba7f80516cbc70e8
https://doi.org/10.1182/bloodadvances.2019000525
https://doi.org/10.1182/bloodadvances.2019000525
Autor:
David Bing Zhen, Ramya Thota, Chris del Corral, Dong Geng, Tairan Yang, Chuan Wang, Gianni Amato, Muhammad Akram, Donna S Miller, Lida Bubuteishvili-Pacaud, Michael K. Gibson
Publikováno v:
Journal of Clinical Oncology. 41:TPS480-TPS480
TPS480 Background: Locally advanced and metastatic gastric, esophageal, gastroesophageal junction, and pancreatic adenocarcinomas (GC, EC, GEJC, and PC) have poor overall survival, and more effective therapies are needed. Claudin 18.2 (CLDN18.2), a t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4b804af912488ae02366989ff3481248
https://doi.org/10.1200/jco.2023.41.4_suppl.tps480
https://doi.org/10.1200/jco.2023.41.4_suppl.tps480
Autor:
Piers E.M. Patten, Julio C. Chavez, P. Joy Ho, Monalisa Ghosh, Jason Butler, Bastian von Tresckow, Andreas L. Petzer, Arne Kolstad, Alessandra Forcina, Catherine Thieblemont, José A. Pérez-Simón, Sarah J. Nagle, Pier Luigi Zinzani, Lida Bubuteishvili Pacaud, Joseph McGuirk, Aiesha Zia, Charalambos Andreadis, Michael Dickinson, Stephen J. Schuster, Marie José Kersten, Andrés J.M. Ferreri, Hideo Harigae, Loretta J. Nastoupil, Peter A. Riedell, Martin Dreyling, Fritz Offner, Ram Malladi, Andreas Viardot, Takanori Teshima, Koji Kato, Leslie Popplewell, Emmanuel Bachy, Joaquin Martinez-Lopez, Nathan Fowler
Publikováno v:
Blood. 136:1-3
Background: Follicular lymphoma (FL) remains an incurable disease for most patients (pts), characterized by a relapsing and remitting pattern. For pts with relapsed/refractory (r/r) FL, treatment outcomes typically worsen with each subsequent line of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::09dbaa35228b0747d49d193b26644f58
https://doi.org/10.1182/blood-2020-138983
https://doi.org/10.1182/blood-2020-138983
Autor:
Hermann Einsele, Adam D. Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan Mark Schecter, Kevin C. De Braganca, Helen Varsos, Tzu-min Yeh, Pankaj Mistry, Tito Roccia, Christina Corsale, Muhammad Akram, Lida Bubuteishvili-Pacaud, Tonia Nesheiwat, Mounzer E. Agha, Yael C. Cohen
Publikováno v:
Journal of Clinical Oncology. 40:8020-8020
8020 Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study is evaluating cilta-cel safety and efficacy in pts with MM who received 1–3 prior LOT and were len-refractory – a difficult-to-treat population with poor prognos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d019edb6d19610e5fff2b480a6861a10
https://doi.org/10.1200/jco.2022.40.16_suppl.8020
https://doi.org/10.1200/jco.2022.40.16_suppl.8020
Autor:
Niels W.C.J. van de Donk, Mounzer E. Agha, Adam D. Cohen, Yael C. Cohen, Sébastien Anguille, Tessa Kerre, Wilfried Roeloffzen, Jordan Mark Schecter, Kevin C. De Braganca, Helen Varsos, Pankaj Mistry, Tito Roccia, Enrique Zudaire, Christina Corsale, Muhammad Akram, Dong Geng, Tonia Nesheiwat, Lida Bubuteishvili-Pacaud, Pieter Sonneveld, Sonja Zweegman
Publikováno v:
Journal of Clinical Oncology. 40:8029-8029
8029 Background: In cohort B of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study, the efficacy and safety of cilta-cel are being evaluated in patients (pts) with MM who had early relapse after initial therapy. These pts have functionally high-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1b32c5af9707f021bb293c6fa35649e8
https://doi.org/10.1200/jco.2022.40.16_suppl.8029
https://doi.org/10.1200/jco.2022.40.16_suppl.8029
Autor:
Adam B. Cohen, Yunsi Olyslager, Carolyn C. Jackson, Mounzer Agha, Saad Z. Usmani, Jesus G. Berdeja, Muhammad Akram, Arnob Banerjee, Andrzej Jakubowiak, Alicia J. Allred, Thomas Martin, William Deraedt, Parameswaran Hari, Deepu Madduri, Yi Lin, Lida Bubuteishvili Pacaud, Tzu-Min Yeh, Sundar Jagannath, Xiaoling Wu, Enrique Zudaire
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S15-S16
Background Ciltacabtagene autoleucel (cilta-cel) is a CAR-T cell therapy with two B-cell maturation antigen–targeting single-domain antibodies. The phase 1b/2 CARTITUDE-1 study is evaluating cilta-cel in patients (pts) with RRMM. Here we report upd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b25b7bb9f3f3c6d2ba60418702d072f8
https://doi.org/10.1016/s2152-2650(21)02098-x
https://doi.org/10.1016/s2152-2650(21)02098-x
Autor:
Ranjan Tiwari, Isabelle Fleury, Qiufei Ma, Stephan Mielke, Constantine S. Tam, Harald Holte, Gilles Salles, Richard T. Maziarz, Peter Borchmann, Stephen Ronan Foley, Jie Zhang, Veronika Bachanova, Samantha Jaglowski, Michael R. Bishop, Lida Bubuteishvili Pacaud, Ulrich Jaeger, Jason R. Westin, Edmund K. Waller, Takanori Teshima, Stephen J. Schuster, Joseph P. McGuirk
The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related qua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eec53a9711675eaab97dadccb17f5917
https://europepmc.org/articles/PMC7042998/
https://europepmc.org/articles/PMC7042998/
Autor:
Stan B. Kaye, D. Binner, B. Wulff, Laurence Brugières, Patricia Blanc, Jean-Yves Blay, J. Carleer, Franca Ligas, S. Chioato, Jaroslav Sterba, Martina Uttenreuther-Fischer, Birgit Geoerger, Lida Bubuteishvili Pacaud, Y. Kerloeguen, C. Spadoni, Renaud Capdeville, Lynley V. Marshall, Nathalie Gaspar, M.-A. Sevaux, T. Taube, Andrew D.J. Pearson, K. Norga, M.A. O'Connell, J-C. Soria, Chris Copland, Ralf Herold, Gilles Vassal, Raphael Rousseau
Publikováno v:
Annals of Oncology
Annals of oncology
Annals of oncology
The impressive progress recently observed in adult cancers through the introduction of new drugs has not yet been translated to adolescents 12-17 years of age [defined according to the International Conference on Harmonization (ICH) E11]. The current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cddb0b8da4ad8a06c82ceeada6266f5b
http://europepmc.org/articles/PMC5889024
http://europepmc.org/articles/PMC5889024